These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

699 related items for PubMed ID: 36264574

  • 41. Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV Trial.
    Cosentino F, Cannon CP, Cherney DZI, Masiukiewicz U, Pratley R, Dagogo-Jack S, Frederich R, Charbonnel B, Mancuso J, Shih WJ, Terra SG, Cater NB, Gantz I, McGuire DK, VERTIS CV Investigators.
    Circulation; 2020 Dec 08; 142(23):2205-2215. PubMed ID: 33026243
    [Abstract] [Full Text] [Related]

  • 42.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 43. Association Between Hospitalization for Heart Failure and Dipeptidyl Peptidase 4 Inhibitors in Patients With Type 2 Diabetes: An Observational Study.
    Fu AZ, Johnston SS, Ghannam A, Tsai K, Cappell K, Fowler R, Riehle E, Cole AL, Kalsekar I, Sheehan J.
    Diabetes Care; 2016 May 08; 39(5):726-34. PubMed ID: 26740636
    [Abstract] [Full Text] [Related]

  • 44. Cardiovascular Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Older Patients in Routine Clinical Care With or Without History of Atherosclerotic Cardiovascular Diseases or Heart Failure.
    Htoo PT, Buse J, Cavender M, Wang T, Pate V, Edwards J, Stürmer T.
    J Am Heart Assoc; 2022 Feb 15; 11(4):e022376. PubMed ID: 35132865
    [Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46. Cardiovascular and renal effectiveness of empagliflozin in routine care in East Asia: Results from the EMPRISE East Asia study.
    Seino Y, Kim DJ, Yabe D, Tan EC, Chung WJ, Ha KH, Nangaku M, Node K, Klement R, Yasui A, Lei WY, Lee S, Kyaw MH, Deruaz-Luyet A, Brodovicz KG, H-H Sheu W, EMPRISE East Asia study group.
    Endocrinol Diabetes Metab; 2021 Jan 15; 4(1):e00183. PubMed ID: 33532619
    [Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48. [Cardiovascular safety of sitagliptin added to metformin in real world patients with type 2 diabetes].
    Liu Z, Chen X, Zhao H, Zhan S, Sun F.
    Beijing Da Xue Xue Bao Yi Xue Ban; 2024 Jun 18; 56(3):424-430. PubMed ID: 38864127
    [Abstract] [Full Text] [Related]

  • 49. Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study.
    Karasik A, Lanzinger S, Chia-Hui Tan E, Yabe D, Kim DJ, Sheu WH, Melzer-Cohen C, Holl RW, Ha KH, Khunti K, Zaccardi F, Subramanian A, Nirantharakumar K, Nyström T, Niskanen L, Linnemann Jensen M, Hoti F, Klement R, Déruaz-Luyet A, Kyaw MH, Koeneman L, Vistisen D, Carstensen B, Halvorsen S, Langslet G, Fazeli Farsani S, Patorno E, Núñez J, EMPRISE Europe and Asia Study Group.
    Diabetes Metab; 2023 Mar 18; 49(2):101418. PubMed ID: 36608816
    [Abstract] [Full Text] [Related]

  • 50. Risk of Severe Hypoglycemia With Newer Second-line Glucose-lowering Medications in Older Adults With Type 2 Diabetes Stratified by Known Indicators of Hypoglycemia Risk.
    Htoo PT, Paik JM, Alt E, Kim DH, Wexler DJ, Kim SC, Patorno E.
    J Gerontol A Biol Sci Med Sci; 2023 Dec 01; 78(12):2426-2434. PubMed ID: 36866496
    [Abstract] [Full Text] [Related]

  • 51. Impact of polyvascular disease with and without co-existent kidney dysfunction on cardiovascular outcomes in diabetes: A post hoc analysis of EMPA-REG OUTCOME.
    Verma S, Mazer CD, Inzucchi SE, Wanner C, Ofstad AP, Johansen OE, Zwiener I, George JT, Butler J, Zinman B.
    Diabetes Obes Metab; 2021 May 01; 23(5):1173-1181. PubMed ID: 33502090
    [Abstract] [Full Text] [Related]

  • 52. Finerenone efficacy in patients with chronic kidney disease, type 2 diabetes and atherosclerotic cardiovascular disease.
    Filippatos G, Anker SD, Pitt B, McGuire DK, Rossing P, Ruilope LM, Butler J, Jankowska EA, Michos ED, Farmakis D, Farjat AE, Kolkhof P, Scalise A, Joseph A, Bakris GL, Agarwal R.
    Eur Heart J Cardiovasc Pharmacother; 2022 Dec 15; 9(1):85-93. PubMed ID: 36251465
    [Abstract] [Full Text] [Related]

  • 53. Cardiovascular Outcomes of α-Blockers vs 5-α Reductase Inhibitors for Benign Prostatic Hyperplasia.
    Zhang J, Latour CD, Olawore O, Pate V, Friedlander DF, Stürmer T, Jonsson Funk M, Jensen BC.
    JAMA Netw Open; 2023 Nov 01; 6(11):e2343299. PubMed ID: 37962887
    [Abstract] [Full Text] [Related]

  • 54. Lower risk of hospitalization for heart failure, kidney disease and death with sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in type 2 diabetes regardless of prior cardiovascular or kidney disease: A retrospective cohort study in UK primary care.
    Idris I, Zhang R, Mamza JB, Ford M, Morris T, Banerjee A, Khunti K.
    Diabetes Obes Metab; 2021 Oct 01; 23(10):2207-2214. PubMed ID: 33973690
    [Abstract] [Full Text] [Related]

  • 55. Effect of Once-Weekly Exenatide in Patients With Type 2 Diabetes Mellitus With and Without Heart Failure and Heart Failure-Related Outcomes: Insights From the EXSCEL Trial.
    Fudim M, White J, Pagidipati NJ, Lokhnygina Y, Wainstein J, Murin J, Iqbal N, Öhman P, Lopes RD, Reicher B, Holman RR, Hernandez AF, Mentz RJ.
    Circulation; 2019 Nov 12; 140(20):1613-1622. PubMed ID: 31542942
    [Abstract] [Full Text] [Related]

  • 56. Association of Cardiac Biomarkers With Major Adverse Cardiovascular Events in High-risk Patients With Diabetes: A Secondary Analysis of the DECLARE-TIMI 58 Trial.
    Zelniker TA, Wiviott SD, Mosenzon O, Goodrich EL, Jarolim P, Cahn A, Bhatt DL, Leiter LA, McGuire DK, Wilding J, Averkov O, Budaj A, Parkhomenko A, Ray KK, Gause-Nilsson I, Langkilde AM, Fredriksson M, Raz I, Sabatine MS, Morrow DA.
    JAMA Cardiol; 2023 May 01; 8(5):503-509. PubMed ID: 36857035
    [Abstract] [Full Text] [Related]

  • 57. Comparison of cardiovascular and renal outcomes between dapagliflozin and empagliflozin in patients with type 2 diabetes without prior cardiovascular or renal disease.
    Lim J, Hwang IC, Choi HM, Yoon YE, Cho GY.
    PLoS One; 2022 May 01; 17(10):e0269414. PubMed ID: 36251654
    [Abstract] [Full Text] [Related]

  • 58. Comparative cardiovascular outcomes in type 2 diabetes patients taking dapagliflozin versus empagliflozin: a nationwide population-based cohort study.
    Lim J, Choi YJ, Kim BS, Rhee TM, Lee HJ, Han KD, Park JB, Na JO, Kim YJ, Lee H, Kim HK.
    Cardiovasc Diabetol; 2023 Jul 26; 22(1):188. PubMed ID: 37496050
    [Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60. Impact of Heart Failure History at Baseline on Cardiovascular Effects of GLP-1 Receptor Agonists in Type 2 Diabetes: a Meta-analysis.
    Banerjee M, Maisnam I, Mukhopadhyay S.
    Cardiovasc Drugs Ther; 2024 Aug 26; 38(4):739-746. PubMed ID: 36696050
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 35.